Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veru Inc. - Common Stock (NQ: VERU )

0.8437 +0.1032 (+13.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veru Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Veru: Q3 Earnings Insights
Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to... 
Via Benzinga
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
Earnings Outlook For Veru
On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients
Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent,... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Veru: Q2 Earnings Insights
Shares of Veru (NASDAQ:VERU) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share fell 300.00% over the past year to ($0.04),... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Analyzing The Price Action In Veru Stock Today
Veru's Stock Price And Volume Action Veru (NASDAQ:VERU) is current... 
Via Benzinga
Return On Capital Employed Overview: Veru
During Q2, Veru (NASDAQ:VERU) brought in sales totaling $13.34 million. However, earnings decreased 289.37%, resulting in a loss of $1.47 million. In Q1, Veru earned $777.00... 
Via Benzinga
Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19
Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients... 
Via Benzinga
Exposures COVID-19
Veru's FC2 Prescription Sales Boost Q2 Revenues
Veru Inc (NASDAQ: VERU) reported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago. Sales... 
Via Benzinga
Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of... 
Via Benzinga
Cramer Gives His Opinion On ContextLogic, Microvision And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he bets there could be a bit of a run in ContextLogic Inc. (NASDAQ: WISH) because 40% of the float is shorted... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For May 12, 2021
Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter. • Boyd Gaming (NYSE:BYD) is projected to report... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021
Upgrades For Booking Holdings Inc (NASDAQ:BKNG), Jefferies upgraded the previous rating of Hold to Buy. In the fourth quarter, Booking Holdings showed an EPS of $0.57,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.